This presentation summarizes the results of a multi-center, international, rater-blinded, randomized clinical trial that was conducted in patients with non-thymomatous MG who were either receiving or naïve to prednisone.
This presentation provides an overview of the complement cascade and its role in MG. During MG, AChR autoantibodies activate complement proteins, which can damage the post-synaptic surface of the neuromuscular junction leading to disease pathogenesis.
This presentation provides an overview of the role of FcRn in MG. During homeostasis, FcRn plays a pivotal role in preventing the lysosomal degradation of the IgG class of antibodies.
FcRn Blockers
For US Healthcare Professionals Only
The contents of this website are intended for US healthcare professionals only.
By clicking “Continue,” you are confirming that you are a US healthcare professional.
Important note:
This contact form is not intended to be used to order prescribed medications, nor should it be used to report personal health concerns or adverse events, in case of such events:
for patients: if you wish to report an adverse event related to one of our products, please contact your healthcare provider. In addition you can contact us using the webform available here
for healthcare professionals: if you wish to report an adverse event related to one of our products , please follow the current regulatory procedure in force in your country or contact us using the webform available here.
This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.
